Related Experiment Video
Updated: May 9, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Copper phenotype in Alzheimer's disease: dissecting the pathway
Rosanna Squitti1, Renato Polimanti
1Department of Neuroscience, AFaR - "San Giovanni Calibita" Fatebenefratelli Hospital Rome, Italy ; Laboratorio di Neurodegenerazione, IRCCS San Raffaele Pisana Italy.
American Journal of Neurodegenerative Disease
|July 12, 2013
Summary
Alzheimer's disease (AD) involves complex pathogenesis, but copper dyshomeostasis is a key factor. This review explores the role of copper metabolism defects in AD, proposing a distinct copper phenotype for the disease.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Alzheimer's disease (AD) is the most common dementia, with complex and multifactorial pathogenesis.
- Current hypotheses do not fully explain AD etiology, necessitating exploration of novel pathways.
- Biometals, particularly copper, are increasingly implicated in AD onset and progression.
Purpose of the Study:
- To review the role of copper dyshomeostasis in Alzheimer's disease.
- To explain the basis of a proposed copper phenotype in AD.
- To highlight mechanisms of copper pathway disruption in AD pathogenesis.
Main Methods:
- Review of in vivo, in vitro, clinical, and in silico studies on copper metabolism in AD.
- Analysis of genetic defects associated with copper metabolism in AD patients.
- Examination of copper-related oxidative stress and beta-amyloid aggregation mechanisms.
Main Results:
- Defects in copper metabolism are consistently observed in AD patients, both locally and systemically.
- Alterations in copper homeostasis correlate with increased oxidative stress and beta-amyloid pathology.
- Evidence supports the existence of a specific 'copper phenotype' in Alzheimer's disease.
Conclusions:
- Copper dyshomeostasis is a significant characteristic of Alzheimer's disease.
- Disruption of copper pathways contributes to AD pathogenesis.
- Understanding the AD copper phenotype offers potential therapeutic targets and translational outcomes.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...